Response of Desloratadine Syrup in the Relief of Symptoms Associated With Perennial Allergic Rhinitis in Pediatric Patients (Study P04299)

Organon

Status: Completed

Conditions: Rhinitis

Treatments: Drug: Desloratadine (assigned by investigator as part of normal practice)

Study type: Observational

Funder types: Industry

Identifiers

NCT00704769

P04299

Details and patient eligibility

About

Evaluate the safety and general clinical response of desloratadine syrup in the relief of symptoms associated with perennial allergic rhinitis in Indonesian pediatric patients.

Full description

Children, ages 2-11, with a history of perennial allergic rhinitis

Enrollment: 591 patients

Sex: All

Ages: 2 to 11 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Children patients of both sexes aged between 2-11 years, of either gender and any race
• Unequivocal history of perennial allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, pruritus, and lacrimation
• Minimum score for inclusion: 10
• Capable of complying with the dosing regimen
• Free of any clinically significant disease (other than allergic rhinitis)
• Antihistamine must be justified by investigating doctor

Exclusion criteria

• Patients with asthma who require chronic use of inhaled or systemic corticosteroids
• History of frequent, clinically significant sinusitis or chronic purulent postnasal drip
• Patients with rhinitis medicamentosa
• History of hypersensitivity to desloratadine or any of its excipients
• Doctor deems unsuitable

Trial design

591 participants in 1 patient group

1

Description:

Children with a history of perennial allergic rhinitis

Treatment:

Drug: Desloratadine (assigned by investigator as part of normal practice)